BRWA
CCCC icon

B. Riley Wealth Advisors’s C4 Therapeutics CCCC Stock Holding History

B. Riley Wealth Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,000
Closed -$24.4K – 1044
2025
Q3 		$24.4K Hold
11,000
– – ﹤0.01% 1035
2025
Q2 		$15.7K Buy
+11,000
New +$16K ﹤0.01% 1020
2024
Q4 		$39.6K Hold
11,000
– – ﹤0.01% 1124
2024
Q3 		$62.7K Hold
11,000
– – ﹤0.01% 1229
2024
Q2 		$50.8K Buy
+11,000
New +$65.6K ﹤0.01% 1344

Other funds holding CCCC

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

B. Riley Wealth Advisors's CCCC Position: Q4 2025 in Review

B. Riley Wealth Advisors sold out of C4 Therapeutics (CCCC) in Q4 2025, closing a stake of 11,000 shares — an estimated $24.4K sold.

B. Riley Wealth Advisors first reported a position in CCCC in Q2 2024 and held it in 5 quarters. The position peaked at $62.7K in Q3 2024. 101 funds tracked by Wall St. Rank hold CCCC as of Q4 2025.

  • B. Riley Wealth Advisors reported no remaining C4 Therapeutics position as of Q4 2025 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 11,000 C4 Therapeutics shares in Q4 2025, an estimated $24.4K.
  • B. Riley Wealth Advisors first reported a position in C4 Therapeutics in Q2 2024 and held it in 5 quarters.
  • B. Riley Wealth Advisors's C4 Therapeutics position peaked at $62.7K in Q3 2024.
  • 101 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2025.

Based on B. Riley Wealth Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.